
14 Healthy Foods That Are High in Potassium
Potassium is an essential mineral that the body requires for a variety of processes. Since the body can't produce potassium, it has to come from food.
However, most Americans don't get enough potassium from their diets.
This is mainly due to a lack of fruits and vegetables in the typical Western diet.
In the United States, it's recommended that healthy adults consume 4,700 mg daily.
Getting enough dietary potassium is essential for bone and heart health. It's vital for people with high blood pressure, as it may decrease the risk of heart disease and stroke.
This article lists 14 foods that are highest in potassium.
White beans
Beans and lentils are both good sources of potassium.
White beans are one of the best sources of potassium, with 421 mg of potassium in 1/2 cup (130 grams).
White beans contain reasonable amounts of calcium and iron.
Additionally, 1/2 cup of white beans provides 4.9 grams of fiber, which is 18% of your daily requirement. They're also an excellent source of plant-based protein.
The beans' high fiber and antioxidant content can help decrease inflammation, improve colon health, and reduce the risk of heart disease and diabetes.
A recent meta-analysis showed a significant reduction in stroke risk with a higher potassium intake in the diet.
Potatoes and sweet potatoes
White potatoes are one of the best food sources of potassium available.
A large baked potato (299 grams) provides 1,600 mg.
Since potassium is found in both the flesh and skin of a potato, it's most beneficial to consume them washed and unpeeled.
Another starchy tuber rich in potassium is baked sweet potatoes. One of these large vegetables (235 grams) contains 1,110 mg.
But potatoes aren't just good sources of potassium. They also contain vitamins A, C, B6, and manganese.
Beets
Beets, a root vegetable with a naturally sweet flavor, are available in various colors, such as deep red, purple, and white.
A 1/2 cup (85 grams) of sliced and boiled beets contains 259 mg of potassium.
Beets are also rich in folate and manganese. The pigment that gives beets their rich color acts as an antioxidant, which may help fight oxidative damage and inflammation.
Beets are also high in nitrates, which may benefit blood vessel function, high blood pressure, and exercise performance.
Beets' potassium content may also help improve blood vessel function and decrease the risk of heart disease.
Spinach
Spinach is a highly nutritious vegetable.
Cooked spinach is a great option for those wanting to increase their potassium intake. It contains 839 mg of potassium per cup.
It also provides 104% of the DV for vitamin A, over 7 times the DV for vitamin K, almost 19% of the DV for calcium, and around 73% of the DV for manganese.
These nutrients are important for metabolism, vision health, bone health, and the immune system.
Dark leafy green vegetables like spinach also contain antioxidants, including flavonoids, which help protect against cellular damage.
Swiss chard
Swiss chard is a leafy green vegetable that's highly nutritious.
It's packed with nutrients. One cup (175 grams) of cooked Swiss chard contains 961 mg of potassium.
It also contains vitamins A, K, and C, iron, plus magnesium, manganese, and fiber.
Like spinach, kale, and other leafy green vegetables, Swiss chard also contains healthy plant compounds that act as antioxidants to help protect your cells.
Tomatoes and tomato sauce
Tomatoes and tomato products, such as tomato sauce, are full of potassium. One cup (245 grams) of tomato sauce contains 728 mg of potassium.
Tomatoes are also rich in other minerals, like manganese, and vitamins, including vitamins A, C, E, and B6.
What's more, tomatoes contain beneficial plant compounds like lycopene, which may help fight inflammation and reduce prostate cancer risk.
A small study of people with metabolic syndrome who received tomato juice four times a week for 2 months saw significant improvement in inflammation, blood vessel dysfunction, and insulin resistance.
A recent review of studies found that lycopene provided significant antioxidant and anti-inflammatory benefits and lowered the components of metabolic syndrome, including high blood pressure, obesity, and insulin resistance, in both animal and human subjects.
The participants also experienced a decrease in LDL (bad) cholesterol and a slight increase in HDL (good) cholesterol.
The beneficial effects of potassium and lycopene on heart disease risk factors make tomatoes an excellent choice for heart health.
Oranges and orange juice
Citrus fruits like oranges are well known for being high in vitamin C, but they're also a good source of potassium.
One cup (248 grams) of orange juice provides 496 mg of potassium. It's also rich in folate, vitamin A, thiamine, and antioxidants.
Observational studies have found that people who regularly consume orange juice have a higher intake of vitamin C, potassium, calcium, and vitamin D, and are also more likely to have a lower BMI.
Additionally, the high level of antioxidants in oranges and their juice may help improve the body's ability to fight free radicals, inflammation, and heart disease.
Furthermore, consuming orange juice fortified with calcium and vitamin D may help improve bone health, especially since a high potassium intake may also benefit bone health.
But remember that orange juice is higher in sugar and provides less fiber than the whole fruit.
Thus, it's best to focus on eating the fruit rather than drinking juice as a source of vitamins and minerals. If you choose to drink orange juice, ensure it's 100% juice without added sugars.
Bananas
Bananas are known to be a good source of potassium. In fact, one banana has 451 mg of potassium.
This tasty fruit is also rich in vitamin C, vitamin B6, magnesium, fiber, and antioxidants.
While ripe bananas tend to be high in sugar, green bananas are lower in sugar and higher in resistant starch, which may help manage blood sugar and improve gut health.
Green bananas and green banana powder may help enhance fullness, improve constipation and diarrhea, and help some people lose weight.
The banana's convenient, natural packaging makes it an easy and nutritious way to increase your potassium intake on the go.
Avocados
Avocados are incredibly nutritious, tasty, and unique.
They're high in heart-healthy monounsaturated fats and rich in fiber, antioxidants, vitamins C, K, B6, folate, and pantothenic acid.
Avocados are also a good source of potassium. One cup (150 grams) of whole avocado provides 728 mg of potassium.
The high content of antioxidants, healthy fats, and fiber in avocados is most likely responsible for their positive health effects. Studies have shown that avocados may benefit heart health, weight management, and metabolic syndrome.
A 2017 study associates eating avocados with better diet quality, lower BMI, body weight, waist circumference, and a significantly lower risk of metabolic syndrome.
However, more recent studies have found that avocados may not necessarily be linked with lower body weight and instead have a neutral effect on weight, or they may only affect particular populations. In one study, avocados were found to lower weight gain in female participants but not male ones.
The rich potassium content of avocados and their other healthy properties make them an easy choice for helping meet your nutrient needs.
Yogurt
Yogurt is an excellent source of calcium, riboflavin, and potassium. One cup (245 grams) of this creamy treat provides you with 380 mg of potassium.
Because yogurt is a fermented food, it also contains bacteria that may benefit gut health.
Some evidence also suggests that yogurt may be beneficial for managing appetite or weight maintenance. This is likely related more to its high protein than its probiotic content.
When buying yogurt, aim for a plain variety, as fruit-flavored yogurts tend to have lots of added sugar. Greek yogurt may be a better option due to its higher protein content. If you find plain yogurt is too tart, sweeten it with fresh fruit, nuts, a little honey, or maple syrup.
Clams
Clams are an excellent source of potassium. A 3-ounce serving (85 grams) provides 534 mg.
Clams are also extremely rich in other nutrients. One serving offers 99% of the DV for selenium and surpasses the DV for vitamin B12.
They're also a great source of protein and high in healthy omega-3 fats, which are associated with various health benefits, including reducing inflammation and other risk factors associated with related diseases.
Salmon
Salmon is a highly nutritious food. It's packed with high quality protein, healthy omega-3 fats, and many vitamins and minerals, including potassium.
Half of a filet of salmon (178 grams) provides 684 mg of potassium.
A diet rich in fatty fish has also been linked with various health benefits, most notably a decreased risk of heart disease.
In fact, a meta-analysis of 18 studies found that eating 2-3 150 g portions of fish a week was linked to an 8% reduced risk for both fatal and non-fatal cardiovascular disease.
The rich potassium content of salmon may make it beneficial for heart disease, as well.
Coconut water
Coconut water has become a popular health drink. It's sweet and nutty, low in sugar, and high in electrolytes.
The body needs electrolytes to help balance its pH and maintain proper nerve, heart, and muscle function and hydration.
One of these electrolytes is potassium. Drinking 1 cup (240 grams) of coconut water will provide 600 mg of potassium.
Coconut water's high electrolyte content makes it an excellent drink for rehydrating after challenging physical activities.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC) Spero, along with its development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 Existing cash and earned and non-contingent development milestone payments from GSK provide anticipated runway to fund the Company's current operating expenses and capital expenditures into 2028 CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. 'During the second quarter, we announced that the tebipenem Phase 3 PIVOT-PO trial met its primary endpoint, marking a significant milestone for this program. We look forward to working with GSK on next steps for this program which include completion of the Phase 3 data analysis and submission of the data package to the FDA,' said Esther Rajavelu, Chief Executive Officer and Chief Financial Officer of Spero. 'There remains a critical unmet need for an oral carbapenem to treat complicated urinary tract infections, including pyelonephritis. If approved, we believe tebipenem HBr could set a new standard of care for these infections, with the potential to shorten hospital stays, improve patient outcomes, and reduce pressure on healthcare resources.' Pipeline UpdateTebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of cUTI, including pyelonephritis, to help patients potentially reduce the duration of in-patient therapy. Spero granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except certain Asian territories where Meiji holds development and commercialization rights. In May 2025, Spero and its development partner GSK announced that the Phase 3 PIVOT-PO trial met the primary endpoint of non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients with cUTI, including pyelonephritis, on overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit. The IDMC review did not identify any new safety concerns beyond what has been reported in other studies with tebipenem, with diarrhea and headache as the two most reported adverse events. GSK plans to work with U.S. regulatory authorities to include these data as part of a filing in 2H 2025. Full results will be submitted for presentation at an upcoming scientific meeting and for publication in a peer-reviewed journal. For more information on the PIVOT-PO trial, please refer to ID NCT06059846. SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted rapidly in vivo to SPR719, the active moiety, after oral administration. SPR719 targets the ATPase site of DNA gyrase B in mycobacteria, a mechanism that is distinct from that of other antibiotics in use for nontuberculous mycobacterium pulmonary disease (NTM-PD). The oral development program in NTM-PD was suspended in 4Q 2024. This followed a planned interim analysis of 16 patients dosed in the Phase 2a trial, which demonstrated the trial did not meet its primary endpoint. The Company is determining next steps for the program. Corporate Update Esther Rajavelu was appointed as Spero's President and Chief Executive Officer, effective May 2, 2025. Ms. Rajavelu was also elected to the Board of Directors at Spero's 2025 annual meeting of stockholders. She continues to serve as the Company's Chief Financial Officer and Treasurer. As of June 30, 2025, Spero had cash and cash equivalents of $31.2 million. Spero estimates that its existing cash and cash equivalents, together with earned and noncontingent development milestone payments from GSK, including the final development milestone payment under the GSK License Agreement of $23.8 million received in August 2025, will be sufficient to fund its operating expenses and capital expenditures into 2028. Pursuant to the GSK License Agreement, Spero has adjusted the aggregate potential commercial milestone payments contingent upon first sales from up to $150.0 million to up to $101.0 million after PIVOT-PO was stopped early for efficacy. The trial was stopped early following completion of a pre-specified interim analysis with 1,690 patients enrolled in the trial, reducing the overall costs to Spero; the maximum potential milestone payment of $150.0 million was contingent upon the trial continuing to full enrollment with 2,637 patients enrolled in the trial. All other contingent milestone payments remain unchanged. For further details on upcoming milestones, please review the disclosure in our Form 10-Q, filed today. Second Quarter 2025 Financial Results Spero reported a net loss of $1.7 million for the second quarter of 2025 compared to a net loss of $17.9 million for the second quarter of 2024, or a diluted net loss per share of common stock of $0.03 and $0.33, respectively. Total revenue for the second quarter of 2025 was $14.2 million, compared with total revenue of $10.2 million for the second quarter of 2024. The revenue increase for the second quarter of 2025 was primarily due to collaboration revenue from GSK. Research and development expenses for the second quarter of 2025 were $10.7 million, compared to $23.7 million of research and development expenses for the same period in 2024. The decrease in research and development expenses compared with the prior year period was primarily due to reduced clinical expenses related to the PIVOT-PO trial. General and administrative expenses for the second quarter of 2025 were $5.9 million, compared to $5.5 million of general and administrative expenses for the same period in 2024. This increase compared with the prior year-period was primarily due to increased personnel and professional service expense. For further details on Spero's financials, refer to Spero's Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (SEC) today. Conference Call and Live Webcast Spero management will host a conference call and live audio webcast at 4:30 p.m. ET today, August 12, 2025, to discuss the second quarter financial results and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this and request a return call with passcode 0605709. The audio webcast can be accessed live on this and also on the 'Investor Relations' page of the Spero Corporate Website at The archived webcast will also be available on Spero's website for 30 days following the call. Government Agency Research Support The views expressed in this press release are those of the authors and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government. Tebipenem HBr Research SupportSelect tebipenem HBr studies have been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; and Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visit Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing, progress and results of Spero's Phase 3 PIVOT-PO trial; the timing of a planned FDA filing in 2H 2025 for tebipenem HBr; the potential of tebipenem HBr to be the first oral carbapenem antibiotic for US patients with cUTI, including pyelonephritis, and to set a new standard of care; the potential receipt of milestone payments under Spero's license and collaboration agreements; Spero's anticipated cash runway; and the potential benefits of any of Spero's current or future product candidates in treating patients. In some cases, forward-looking statements may be identified by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intent," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual results to differ materially from those indicated by such forward looking statements, including whether tebipenem HBr will advance through the clinical development process, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero's reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved, including, in the case of tebipenem HBr, Spero's reliance on GSK pursuant to the exclusive GSK License Agreement to develop tebipenem HBr and GSK's right thereunder to determine, in its sole discretion, whether to continue the PIVOT-PO trial or otherwise further develop tebipenem HBr; Spero's need for additional funding; the ability to commercialize Spero's product candidates, if approved; Spero's ability to retain key personnel; Spero's leadership transitions; whether Spero's cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the "Risk Factors" set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements. Investor Relations Contact:Shai Biran, PhDSpero Therapeutics IR@ Media Inquiries: media@ Spero Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (Unaudited) June 30,2025 December 31,2024 Cash and cash equivalents $ 31,194 $ 52,889 Other assets 30,925 57,654 Total assets $ 62,119 $ 110,543 Total liabilities 29,291 64,420 Total stockholder's equity 32,828 46,123 Total liabilities and stockholders' equity $ 62,119 $ 110,543 Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues: Grant revenue $ 2,387 $ 4,180 $ 3,150 $ 9,243 Collaboration revenue - related party 11,802 5,903 16,901 9,967 Collaboration revenue — 114 12 254 Total revenues 14,189 10,197 20,063 19,464 Operating expenses: Research and development 10,672 23,725 24,278 41,057 General and administrative 5,878 5,533 12,702 11,450 Restructuring 83 — 258 — Total operating expenses 16,633 29,258 37,238 52,507 Loss from operations (2,444 ) (19,061 ) (17,175 ) (33,043 ) Total other income, net 744 1,199 1,609 2,512 Net loss $ (1,700 ) $ (17,862 ) $ (15,566 ) $ (30,531 ) Net loss per share attributable to common shareholders per share, basic and diluted $ (0.03 ) $ (0.33 ) $ (0.28 ) $ (0.57 ) Weighted average shares outstanding, basic and diluted: 56,026,767 53,957,766 55,703,275 53,740,901 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the disclosure of significant stock sales by top executives, including CEO Andrew Dudum. According to SEC filings, CEO Andrew Dudum sold 660,000 shares for a total of approximately $33.4 million. The selling was not limited to the CEO, as Chief Medical Officer Patrick Carroll also sold 60,000 shares valued at around $3.2 million, while the company's chief commercial officer also recently parted with shares. Such significant stock sales by a company's top leadership can raise concerns among investors about the firm's future prospects. These transactions come at a challenging time for the telehealth company, which has recently faced legal pressure from drugmaker Novo Nordisk and a class-action lawsuit related to its compounded weight-loss drug offerings. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it's free. What Is The Market Telling Us Hims & Hers Health's shares are extremely volatile and have had 95 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 4 months ago when the stock gained 34.9% on the news that Novo Nordisk announced plans to offer its weight loss drug Wegovy through Hims & Hers Health's platform, expanding access to one of its fastest-growing products. By partnering with a popular telehealth company, Novo could speed up Wegovy's adoption, leading to more prescriptions. For investors, the deal signals a clear strategy to expand distribution and grab more market share, a move that could also boost sales growth for Hims & Hers (HIMS). Hims & Hers Health is up 91.4% since the beginning of the year, but at $48.23 per share, it is still trading 29.8% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health's shares 5 years ago would now be looking at an investment worth $4,541. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Woman Frames Husband's Tattooed Skin After His Death to Preserve His Memory. She Was 'Shocked' by the Result (Exclusive)
'When we want to know he's here, we can hold the frame, and it does so much more than a picture,' Angelica Radevski tells PEOPLENEED TO KNOW Angelica Radevski, a 35-year-old nurse, decided to frame the skin of her husband's tattoo after he suddenly died earlier this year She tells PEOPLE that she learned about the option when she was a kid, and it always 'stuck with' her 'When we want to know he's here, we can hold the frame, and it does so much more than a picture,' says RadevskiAs Angelica Radevski remembers her late husband, she doesn't hesitate to mention his love of sports. 'It was constantly ESPN on the radio or the TV,' she tells PEOPLE. And his favorite team to follow was the Pittsburgh Steelers. Radevski, a 35-year-old nurse from Wheeling, and her husband had been close friends their entire lives — she had actually worked for his dad at a local restaurant for a decade. Together, the couple raised a son, now 10 years old, and they tied the knot in 2021. 'He was just the type of person where if you met him, even just one time at the grocery store or the gym, he left an impression of being such a loving, happy person,' says Radevski. Her husband was also covered in tattoos — 'from his neck all the way down to his feet,' says Radevski. 'Every tattoo that he had was a piece of his life. It was like therapy. It was his healing.' So when her husband died unexpectedly at age 55 earlier this year, Radevski continues, it only felt natural to frame one of his tattoos for his memory to continue to live alongside her and their son in their home. Radevski says she was a kid when she first learned from Ripley's Believe It or Not! about the Ohio-based company, Save My Ink Forever, which allows loved ones to preserve the skin of a tattoo in a frame after their death. 'I never questioned why it stuck with me,' says Radevski. While they were married, she brought up the idea of framing a tattoo to her husband several times, and 'he thought it was really cool,' she adds. After her husband's funeral, Radevski had the chance to use a marker to outline the tattoo they wanted to frame — a Steelers helmet on his right arm from his first sleeve, which their son Preston remembered was his favorite. Then the mortician removed the skin, placed it in a preservation kit, and mailed it to Save My Ink Forever, before her husband's body was cremated. After roughly 90 days, the company reached out to Radevski: they were ready 'to bring him home,' she says. 'When he handed it to us, I was shocked,' she recalls. 'And it was a good shock — so many things you didn't know you were missing instantly felt better.' And when she and her son took a closer look at the Steelers tattoo, preserved behind the glass of a dark wooden frame, Preston noticed that you could even make out his original hair on the skin. 'Then I was laughing,' continues Radevski. 'With his tattoos, my husband would shave his arms and legs — and you could see the spots that he missed. It took it to a different level. It was like, 'OK, he's really home.' ' In the wake of her husband's death, Radevski decided to share her process of grieving on TikTok — because she knew that if she was feeling alone, she tells PEOPLE, there were others who were going through the same thing. She adds that, because her husband didn't have life insurance, her family was hit by an extreme financial burden, and she wanted to use her platform to spread awareness about the need for planning in the case of tragedies like hers. 'Instead of planning for a wedding for a year, why don't we start planning and making it normal and not so ugly to talk about death,' says Radevski. 'You can be prepared — both financially and with what you want for your body.' When she received her husband's framed tattoo, she shared it with her followers — and the video took off, garnering nearly 30 million views. Like any reaction to a viral post, some of the comments were negative: likening her to Jeffrey Dahmer or calling the process mutilation, says Radevski. But those were 'outweighed' by the love she received from others who felt lucky to learn that this was an option, she explains. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. 'Some were like, 'I wish I had known about this — I just lost my husband and my son,' ' says Radevski. And the comments that warmed her heart the most, she continues, were the ones from rival sports fans who sent their condolences but still couldn't get on board with rooting for the Steelers: 'When they say, 'I'm so sorry for you and your son and I'm praying for you, but go Bengals,' ' she points out of some of the comments. Though she recognizes that framing a tattoo might not be for everyone, Radevski says she hopes her videos can help normalize the process for those who might get a similar kind of solace after losing a loved one. 'Just because it's not what you want, you don't have to make me feel bad about it,' says Radevski. 'We feel him here a lot, spiritually and energetically,' she continues. 'But this is that piece that we really, really needed. When we want to know he's here, we can hold the frame, and it does so much more than a picture.' Read the original article on People